Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 15/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | HTR1D | P28221 | 3/20 | 0.35 |
| ▸ | HTR1B | P28222 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078773 | 0.84 | F10 (0.46) | F10F2 | |
| SCHEMBL6078848 | 0.83 | F10 (0.48) | F10F2 | |
| SCHEMBL7258000 | 0.82 | F10 (0.48) | F10HTR7 | |
| SCHEMBL6079702 | 0.81 | F10 (0.58) | F10 | |
| SCHEMBL6078361 | 0.79 | F10 (0.45) | F10 | |
| SCHEMBL6079503 | 0.79 | F10 (0.46) | F10AKR1B1 | |
| SCHEMBL7257788 | 0.78 | CYP2C19 (0.51) | F10 | |
| SCHEMBL6079295 | 0.77 | F10 (0.40) | F10 | |
| SCHEMBL6078185 | 0.77 | F10 (0.42) | F10F2 | |
| SCHEMBL6079740 | 0.76 | F10 (0.36) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858599-B2 | Inhibitor for activated blood coagulation factor X | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | claimed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | claimed |
| US-7122662-B2 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20050148769-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6858599-B2 | Inhibitor for activated blood coagulation factor X | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030045520-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | F10 23/4885HTR6 4429/4885F2 7/4885 |
| US-20030045520-A1 | Tricyclic compound having spiro union | F2, TFPI, F11 | F10 7/4885HTR6 3594/4885F2 1/4885 |
| US-20050148769-A1 | Tricyclic compound having spiro union | TFPI, F2, F12 | F10 7/4885HTR6 3813/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.